Author Archives: Warren Woessner

Kathleen “Kay” Terry, Esq. (1934-2018)

Posted on June 12, 2018 by Warren Woessner

We should all note and be saddened by the death of Kay Terry, who was a “godmother” to Schwegman, Lundberg & Woessner from our start in 1993, when she was a head of life science patenting and licensing in the … Continue reading →

Posted in People, Uncategorized | 1 Comment

PTO Issues Section 101 Memorandum after Vanda Decision

Posted on June 11, 2018 by Warren Woessner

I have posted twice recently on the Fed. Cir.’s opinion in Vanda Pharms., Inc. v. West-Ward Pharm. Int’l, Ltd., Appeal no. 2016-2107 (Fed. Cir., April 18, 2018). The Fed. Cir. affirmed the district court’s ruling that Vanda’s claims in U.S. … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , | Leave a comment

Ex Parte Galloway – Berkheimer Meet s. 103 Part II

Posted on June 4, 2018 by Warren Woessner

In Ex parte Galloway, Appeal No. 2017-004696 (PTAB, May 24, 2018), the Board reversed the examiner’s rejections of claims to a method of diagnosing bladder cancer. The method comprised isolating cells from the urine of a subject, dispersing at least … Continue reading →

Posted in PTAB, Section 103 | Tagged , , , | Leave a comment

Ex Parte Smith: What We’ve Got Here Is A Failure To Communicate!

Posted on May 29, 2018 by Warren Woessner

In Ex parte Smith, Appeal No. 2016-007565 (PTAB, May 16, 2016), the Board reversed the examiner’s s.101 and 103 rejections of a claim to a modified flavivirus envelop (E) protein comprising a mutated envelop protein, where the unmodified E-To domain … Continue reading →

Posted in Patent Eligible Subject Matter | Tagged , , , , | Leave a comment